Sight Diagnostics
Last updated: May 8, 2026
Sight Diagnostics develops AI-driven, compact blood-analysis systems that produce rapid hematology and immune-cell insights from a small finger-prick sample, designed for clinical point-of-care and resource-limited settings.
Visit WebsiteCompany Overview
Sight Diagnostics operates at the intersection of optical microscopy, laboratory hematology and applied machine learning. The company's platform uses high-resolution live-cell imaging combined with trained computer-vision models to classify and quantify blood cell populations and morphological features from capillary (finger-prick) blood. Unlike reagent-dependent lab analyzers, the approach emphasizes image-first acquisition and software interpretation to reduce consumable needs and shrink the footprint of hematology testing.
Commercially, Sight targets hospitals, emergency departments and outpatient clinics where fast CBC (complete blood count) and morphology information improves triage and treatment decisions. The company has also commercialized compact devices intended for decentralized care and clinics in regions with limited lab infrastructure; these are positioned to reduce turnaround time for critical diagnostics and to support workflows where standard automated hematology analyzers are impractical.
On competition and positioning, Sight differentiates through an emphasis on live immune-cell phenotyping and AI signatures rather than only delivering basic numeric counts. This creates opportunities for more granular immune monitoring (for example, detecting early sepsis signal patterns or immune activation signatures) that incumbent hematology manufacturers have not historically prioritized in portable devices. Commercial rivals include established in-vitro diagnostics firms that offer robust distribution and regulatory experience, and newer digital microscopy companies focused on AI-assisted cell review.
Traction signals include announcements and product releases demonstrating a shift from the earlier OLO consumer/POC device toward platforms emphasizing immune-cell analysis and software-led analytics. This trajectory implies the company is moving from device-first validation toward a data-and-model-driven product roadmap. From a defense and security perspective, the platform's ability to deliver rapid hematology and immune-status data at point-of-care—without full laboratory infrastructure—has clear applicability for expeditionary medicine, forward-deployed casualty assessment, and outbreak-response screening in austere environments.
Dual-Use Assessment
Sight's core capability—rapid, software-driven blood characterization from minimal samples—maps directly to civilian clinical triage and to military medical needs where lab infrastructure is absent. Specific defense applications include forward triage, monitoring force health and rapid hematology support during mass-casualty or infectious-disease responses. The technology itself is diagnostic (medical) rather than weapons-related, so dual-use considerations focus on medical mission enablement and logistics advantages rather than offensive capabilities.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
Sight combines a defensible software moat—proprietary labeled image datasets and trained hematology/immune models—with a hardware integration that opens non-lab markets. For strategic readers focused on medical readiness or humanitarian assistance capabilities, the company offers a clear route to deployable diagnostics that improve operational resilience. Remaining commercialization risk is substantial but addressable with regulatory progress and scale partnerships.
Strategic Value to U.S.-Israel Alliance
The platform can materially reduce logistical burden for deployed medical units by removing dependence on centralized laboratories, enabling faster diagnostics and decision cycles. For allied militaries or humanitarian organizations, that translates to improved casualty management, quicker outbreak containment, and reduced medevac load. Strategic investors get both a commercial healthcare upside and mission-aligned dual-use impact.
Key Technologies
- High-resolution live-cell optical microscopy
- Computer vision for hematology classification
- Deep learning immune-signature models
- Low-volume capillary blood sampling workflows
- Edge-deployed inference and compact device integration
Use Cases & Applications
- Rapid complete blood count (CBC) and morphology at point-of-care
- Immune-status profiling for early sepsis or infection surveillance
- Field and expeditionary medical triage for military units
- Emergency department rapid decision support
- Remote-clinic diagnostics in low-resource settings
- Clinical trial biomarker collection where fast longitudinal sampling is required
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- Official website Primary public reference for company identity, positioning, and current web presence.
- Profile update timestamp Last updated in the Claw & Talon database on May 8, 2026.
Investor Lens
What this entry is
Private startup
Why it may matter
Sight Diagnostics may matter as a Health & BioTech entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify traction
- Verify cap table/funding
- Verify technical claims
- Verify regulatory/export-control issues
- Verify customer concentration
Main investor questions
- Is the company currently active, independently financeable, and raising or not raising on terms you can verify?
- What customer, revenue, product, and technical evidence supports the company story?
- What valuation, cap table, rights, and follow-on assumptions would govern any private exposure?
- Does the dual-use claim map to actual commercial and government/defense/resilience buyer evidence?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies Sight Diagnostics's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Where does the product create real defense, intelligence, critical-infrastructure, or emergency-response value beyond ordinary commercial adoption?
- What regulatory, procurement, and buyer-adoption constraints could slow deployment in strategic or government-adjacent markets?
- What would disconfirm the priority signal: weak customer references, thin technical differentiation, poor capital efficiency, or limited allied-market access?
Related sector
See the Health & BioTech sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.